Avanos Medical, Inc. (AVNS)
Jul 27, 2026 - AVNS was delisted (reason: acquired by American Industrial Partners)
24.99
+0.01 (0.04%)
Inactive · Last trade price on Jul 24, 2026
Avanos Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 715.9 | 701.2 | 687.8 | 673.3 | 684.1 | 587 | |
Revenue Growth | 3.87% | 1.95% | 2.15% | -1.58% | 16.54% | -17.88% |
Cost of Revenue | 357.6 | 347.3 | 306.5 | 293.6 | 289.9 | 287.8 |
Gross Profit | 358.3 | 353.9 | 381.3 | 379.7 | 394.2 | 299.2 |
Selling, General & Admin | 326.9 | 325.8 | 330 | 335 | 326.5 | 257.2 |
Research & Development | 11.4 | 11.6 | 12.4 | 27.2 | 29.2 | 30.6 |
Other Operating Expenses | 3.6 | 1 | 3 | 3.3 | 3 | 7.3 |
Operating Expenses | 341.9 | 338.4 | 345.4 | 365.5 | 358.7 | 295.1 |
Operating Income | 16.4 | 15.5 | 35.9 | 14.2 | 35.5 | 4.1 |
Interest Expense | -7.2 | -7.8 | -12.2 | -15 | -10 | -3.3 |
Interest & Investment Income | 1.9 | 3.2 | 5.1 | 2.9 | 1.2 | 0.2 |
EBT Excluding Unusual Items | 11.1 | 10.9 | 28.8 | 2.1 | 26.7 | 1 |
Merger & Restructuring Charges | -2.4 | -1.5 | 0.8 | - | - | -28.1 |
Impairment of Goodwill | -77 | -77 | -336.5 | - | - | - |
Asset Writedown | - | - | -100.2 | - | - | - |
Legal Settlements | - | 1.4 | - | -10 | - | -15 |
Other Unusual Items | - | - | 3.8 | - | - | - |
Pretax Income | -68.3 | -66.2 | -403.3 | -7.9 | 26.7 | -42.1 |
Income Tax Expense | 6.1 | 6.7 | -17 | 2 | 5.2 | -11.2 |
Earnings From Continuing Operations | -74.4 | -72.9 | -386.3 | -9.9 | 21.5 | -30.9 |
Earnings From Discontinued Operations | - | - | -5.8 | -51.9 | 29 | 37.2 |
Net Income | -74.4 | -72.9 | -392.1 | -61.8 | 50.5 | 6.3 |
Net Income to Common | -74.4 | -72.9 | -392.1 | -61.8 | 50.5 | 6.3 |
Net Income Growth | - | - | - | - | 701.59% | - |
Shares Outstanding (Basic) | 46 | 46 | 46 | 47 | 47 | 48 |
Shares Outstanding (Diluted) | 46 | 46 | 46 | 47 | 47 | 49 |
Shares Change | 0.92% | 0.65% | -1.29% | -1.48% | -2.67% | 1.67% |
EPS (Basic) | -1.60 | -1.57 | -8.52 | -1.33 | 1.08 | 0.13 |
EPS (Diluted) | -1.60 | -1.57 | -8.53 | -1.33 | 1.08 | 0.13 |
EPS Growth | - | - | - | - | 722.10% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 7.5 | 43.1 | 82.9 | 14.6 | 71.6 | 66.3 |
Free Cash Flow Per Share | 0.16 | 0.93 | 1.80 | 0.31 | 1.51 | 1.36 |
Gross Margin | 50.05% | 50.47% | 55.44% | 56.39% | 57.62% | 50.97% |
Operating Margin | 2.29% | 2.21% | 5.22% | 2.11% | 5.19% | 0.70% |
Profit Margin | -10.39% | -10.40% | -57.01% | -9.18% | 7.38% | 1.07% |
Free Cash Flow Margin | 1.05% | 6.15% | 12.05% | 2.17% | 10.47% | 11.29% |
EBITDA | 55.9 | 54.4 | 81.4 | 57.7 | 76.7 | 42.4 |
EBITDA Margin | 7.81% | 7.76% | 11.83% | 8.57% | 11.21% | 7.22% |
D&A For EBITDA | 39.5 | 38.9 | 45.5 | 43.5 | 41.2 | 38.3 |
EBIT | 16.4 | 15.5 | 35.9 | 14.2 | 35.5 | 4.1 |
EBIT Margin | 2.29% | 2.21% | 5.22% | 2.11% | 5.19% | 0.70% |
Effective Tax Rate | - | - | - | - | 19.48% | - |